Human Molecular Genetics, 2000, Vol. 9, No. 10 1515-1524
© 2000 Oxford University Press
A novel ryanodine receptor mutation and genotype–phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree
Institute of Molecular BioSciences, Massey University, Private Bag 11-222, Palmerston North, New Zealand, 1Department of Anaesthesia and Intensive Care, Palmerston North Hospital, Ruahine Street, Palmerston North, New Zealand, 2Department of Neurology, Auckland Hospital, Private Bag 92024, Auckland, New Zealand, 3Ngati Raukawa, Ki Te Tonga, Aoteoroa, New Zealand and 4Department of Biochemistry, University College Cork, Cork, Ireland
Malignant hyperthermia (MH) is a pharmacogenetic disorder that predisposes to a sometimes fatal hypermetabolic reaction to halogenated anaesthetics. MH is considered to originate from abnormal regulation of skeletal muscle Ca2+ release. Current diagnosis of MH susceptibility (MHS) relies on in vitro contracture testing (IVCT) of skeletal muscle. The ryanodine receptor (RYR1) encoding the major Ca2+ release channel in the skeletal muscle sarcoplasmic reticulum has been shown to be mutated in a number of MH pedigrees. The large Maori pedigree reported here is the largest MHS pedigree investigated to date and comprises five probands who experienced clinical episodes of MH and 130 members diagnosed by the IVCT. Sequencing of the 15 117 bp RYR1 cDNA in a MHS individual from this pedigree identified a novel C14477T transition that results in a Thr4826 to Ile substitution in the C-terminal region/transmembrane loop of the skeletal muscle ryanodine receptor. This is the first mutation in the RyR1 C-terminal region associated solely with MHS. Although linkage analysis showed strong linkage (max LOD, 11.103 at 
= 0.133) between the mutation and MHS in the pedigree using the standardized European IVCT phenotyping protocol, 22 MHS recombinants were observed. The relationship between the IVCT response and genotype was explored and showed that as IVCT diagnostic cut-off points were made increasingly stringent, the number of MHS discordants decreased with complete concordance between the presence or absence of the C14477T mutation and MHS and MH normal phenotypes, respectively, using a cut-off of 1.2 g tension at 2.0 mM caffeine and 1.8 g tension at 2.0% halothane. Many MHS pedigrees investigated have been excluded from linkage to the RYR1 gene on the basis of a small number of recombinants; however, the linkage analysis reported here suggests that other recombinant families excluded from linkage to the RYR1 gene may actually demonstrate linkage as the number of members tested within the pedigrees increases. The high number of discordants observed using the standardized diagnostic cut-off points is likely to reflect the presence of a second MHS susceptibility locus in the pedigree.
+ Present address: Clinical Pharmacology Unit, Level 6, Centre for Clinical Investigation (ACCI), Addenbrooke’s Hospital, Box 110, Hill’s Road, Cambridge CB2 2QQ, UK
§ To whom correspondence should be addressed. Tel: +64 06 3505515; Fax: +64 06 350 5688; Email: k.m.stowell@massey.ac.nz
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Endo Calcium-Induced Calcium Release in Skeletal Muscle Physiol Rev, October 1, 2009; 89(4): 1153 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Carpenter, R. L. Robinson, R. J. Quinnell, C. Ringrose, M. Hogg, F. Casson, P. Booms, D. E. Iles, P. J. Halsall, D. S. Steele, et al. Genetic variation in RYR1 and malignant hyperthermia phenotypes Br. J. Anaesth., October 1, 2009; 103(4): 538 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yang, T. A. Ta, I. N. Pessah, and P. D. Allen Functional Defects in Six Ryanodine Receptor Isoform-1 (RyR1) Mutations Associated with Malignant Hyperthermia and Their Impact on Skeletal Excitation-Contraction Coupling J. Biol. Chem., July 3, 2003; 278(28): 25722 - 25730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tammaro, A. Bracco, S. Cozzolino, M. Esposito, A. Di Martino, G. Savoia, L. Zeuli, G. Piluso, S. Aurino, and V. Nigro Scanning for Mutations of the Ryanodine Receptor (RYR1) Gene by Denaturing HPLC: Detection of Three Novel Malignant Hyperthermia Alleles Clin. Chem., May 1, 2003; 49(5): 761 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Davis, R. Brown, A. Dickson, H. Horton, D. James, N. Laing, R. Marston, M. Norgate, D. Perlman, N. Pollock, et al. Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees Br. J. Anaesth., April 1, 2002; 88(4): 508 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Kindler, T. Girard, D. Gong, and A. Urwyler The Differential Effect of Halothane and 1,2-Dichlorohexafluorocyclobutane on In VitroMuscle Contractures of Patients Susceptible to Malignant Hyperthermia Anesth. Analg., April 1, 2002; 94(4): 1028 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tilgen, F. Zorzato, B. Halliger-Keller, F. Muntoni, C. Sewry, L. M. Palmucci, C. Schneider, E. Hauser, F. Lehmann-Horn, C. R. Muller, et al. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis Hum. Mol. Genet., December 1, 2001; 10(25): 2879 - 2887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Monnier, N. B. Romero, J. Lerale, P. Landrieu, Y. Nivoche, M. Fardeau, and J. Lunardi Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor Hum. Mol. Genet., October 1, 2001; 10(22): 2581 - 2592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Avila, J. J. O'Brien, and R. T. Dirksen Excitation-contraction uncoupling by a human central core disease mutation in the ryanodine receptor PNAS, March 27, 2001; 98(7): 4215 - 4220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Priori, C. Napolitano, N. Tiso, M. Memmi, G. Vignati, R. Bloise, V. Sorrentino, and G. A. Danieli Mutations in the Cardiac Ryanodine Receptor Gene (hRyR2) Underlie Catecholaminergic Polymorphic Ventricular Tachycardia Circulation, January 16, 2001; 103(2): 196 - 200. [Abstract] [Full Text] [PDF]
|
|